Join to access to all OVN content. Join for Free
Aspiring MSL Insights: Acing Behavioral Based Job Interviews

Aspiring MSL Insights: Acing Behavioral Based Job Interviews


Share This Article


Aspiring MSL Insights: Acing Behavioral Based Job Interviews 🎯💼

👉 If you’re an aspiring MSL going into your first MSL interview, you should be preparing for #BehavioralBased #JobInterview #Questions. What are those?

👉 Michael Pietrack, the Medical Affairs recruiting lead at Kaye/Bassman International and the host of the Pharmaverse podcast, answers the question for you in this short video.

👉 A behavioral-based style interview is one that focuses on how you've handled situations in the past, rather than just discussing your skills or qualifications in theory. The idea behind this style of interviewing is that past behavior is the best predictor of future behavior. During these interviews, you'll be asked to provide specific examples from your previous work or life experiences to demonstrate how you handled certain situations, challenges, or tasks.

👉 These types of questions are easy to spot, they generally start with one of these three phrases: 👉 "Tell me about a time when..." 👉 "Give me an example of..." 👉 "Describe a situation where..."

👉 Here’s what to do: Use concrete examples rather than hypothetical answers, and keep your responses between 1-2 minutes in length. ⏱️

👉 One way to help your answer from being long and tangential is using the STAR model to structure your responses. 🌟

📗 STAR Model:

◾ (S) Situation: Describe the context or challenge, but don’t spend too much time or add more detail than necessary.

◾ (T) Task: Explain the task or goal you were working toward. This should be one sentence.

◾ (A) Action: This is the most important point. Detail the specific actions you took to address the situation.

◾ (R) Result: Share the outcomes or results of your actions. This could also be one sentence.

Follow that model when answering, and you’ll look like a pro in your MSL interview. 🏆

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN